Eli Lilly And Co (LLY) Shares Sold by Cobblestone Capital Advisors LLC NY

Share on StockTwits

Cobblestone Capital Advisors LLC NY lessened its position in Eli Lilly And Co (NYSE:LLY) by 14.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,912 shares of the company’s stock after selling 485 shares during the quarter. Cobblestone Capital Advisors LLC NY’s holdings in Eli Lilly And Co were worth $378,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Athena Capital Advisors LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth $26,000. Wakefield Asset Management LLLP acquired a new position in Eli Lilly And Co during the 4th quarter worth $27,000. Larson Financial Group LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth $29,000. Trust Department MB Financial Bank N A grew its stake in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after purchasing an additional 82 shares in the last quarter. Finally, Acima Private Wealth LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth $33,000. Hedge funds and other institutional investors own 80.69% of the company’s stock.

In other news, SVP Christi Shaw sold 7,577 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $117.14, for a total value of $887,569.78. Following the completion of the sale, the senior vice president now directly owns 500 shares of the company’s stock, valued at approximately $58,570. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. Insiders sold a total of 445,959 shares of company stock valued at $57,322,302 over the last three months. Company insiders own 0.11% of the company’s stock.

NYSE:LLY opened at $116.79 on Monday. The stock has a market cap of $113.38 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 2.07 and a beta of 0.27. Eli Lilly And Co has a 1 year low of $81.65 and a 1 year high of $132.13. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.31 EPS. As a group, research analysts forecast that Eli Lilly And Co will post 5.66 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Friday, May 17th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.21%. The ex-dividend date is Thursday, May 16th. Eli Lilly And Co’s payout ratio is currently 46.49%.

Several research analysts recently commented on the company. Citigroup set a $124.00 target price on Eli Lilly And Co and gave the stock a “hold” rating in a research note on Tuesday, February 26th. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Guggenheim cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price for the company. in a research note on Thursday, April 11th. Barclays reissued a “buy” rating and set a $140.00 target price on shares of Eli Lilly And Co in a research note on Sunday, April 14th. Finally, Credit Suisse Group set a $121.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $118.15.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/4353890/eli-lilly-and-co-lly-shares-sold-by-cobblestone-capital-advisors-llc-ny.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How Do I Invest in Dividend Stocks

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report